Influencing Factors of Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease based on The Logistic Regression
DOI:
https://doi.org/10.54097/a7877307Keywords:
T2DM, NAFLD, logistic regression analysis.Abstract
Based on the logistic regression equation, this paper analyzes the influencing factors of Type 2 Diabetes Mellitus (T2DM) & non⁃alcoholic fatty liver disease (NAFLD) NAFLD. The electronic medical record data of 602 patients with T2DM from 2018 to 2021 in a hospital in Qingdao were divided into the T2DM group (208 cases) and the T2DM combined with NAFLD group (394 cases). The results show that there are no significant differences in SBP, DBP, total cholesterol and fasting blood glucose between the two groups, while the differences in gender, age, BMI, and triglyceride (TG) were statistically significant. Multivariate logistic regression analysis finally determined BMI, TG, and gender as independent influencing factors for T2DM combined with NAFLD, and the regression equation was: Logit(P)=-12.893+0.415×BMI + 0.893×log-TG - 0.405×Gender, (male=0). This study suggests that obesity and lipid metabolism disorders are important risk factors for T2DM combined with NAFLD, and male patients are more likely to have NAFLD, which provides a reference for clinical prevention and treatment.
Downloads
References
[1] Qun L, Xuemei L. Analysis of risk factors for non-alcoholic fatty liver disease in Tibetan population with type 2 diabetes. Tibetan Medicine, 2025, 46(02): 42-43.
[2] Kumar N, Tan J, Chen Z, et al. Intraoperative cell-salvaged autologous blood transfusion is safe in metastatic spine tumour surgery: early outcomes of prospective clinical study. Eur Spine J, 2023, 32(7): 2493-2502.
[3] Zhou J. A review of the application of autologous blood transfusion. Braz J Med Biol Res, 2016, 49(9): e5493.
[4] Guolan C, Yanyan L, Yanqing H, et al. Analysis of influencing factors of newly diagnosed type 2 diabetes mellitus combined with non-alcoholic fatty liver disease. Clinical Medical Research and Practice, 2024, 9(18): 1-4.
[5] Khneizer G, Rizvi S, Gawrieh S. Non-alcoholic fatty liver disease and diabetes mellitus. Adv Exp Med Biol, 2021, 1307: 417-440.
[6] Powell E E, Wong V W, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021, 397(10290): 2212-2224.
[7] Fatty Liver and Alcoholic Liver Disease Group, Hepatology Branch of the Chinese Medical Association; Expert Committee on Fatty Liver Disease of the Chinese Medical Doctor Association. Guidelines for the prevention and treatment of non-alcoholic fatty liver disease (2018 updated version). Chinese Journal of Hepatology, 2018, 26(3): 195-203.
[8] Polyzos S A, Kountouras J, Mantzoros C S. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism, 2019, 92: 82-97.
[9] Angelico F, Baratta F, Pastori D, et al. Statins and non-alcoholic fatty liver disease. Liver Int, 2019, 39(9): 1787-1795.
[10] Taneja V. Letter to the editor: intrahepatic lipid content after insulin glargine addition to metformin in type II diabetes mellitus with nonalcoholic fatty liver disease. Hepatology, 2020, 71(3): 1128.
[11] Mantovani A, Byrne C D, Bonora E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care, 2018, 41(2): 372-382.
[12] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
[13] Zachou M, Flevari P, Nasiri-Ansari N, et al. The role of anti-diabetic drugs in NAFLD: Have we found the Holy Grail? A narrative review. Eur J Clin Pharmacol, 2024, 80(1): 127-150.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
